{"title":"Clinical Implication of Liver Metastasis in the Treatment of Gastric Cancer.","authors":"Chi Hoon Maeng","doi":"10.5230/jgc.2023.23.e21","DOIUrl":null,"url":null,"abstract":"The RAINBOW study is a phase 3 trial comparing the combination therapy of ramucirumab plus paclitaxel with paclitaxel monotherapy as palliative second-line treatment in patients with gastric or gastroesophageal junction adenocarcinoma [1]. A significant increase in both the median overall survival (OS, 9.6 vs 7.4 months) and progression-free survival (PFS, 4.4 vs. 2.9 months) was observed in patients who received ramucirumab plus paclitaxel. Based on this pivotal study, ramucirumab plus paclitaxel is the standard second-line treatment. The liver is one of the most common sites of metastasis of gastrointestinal cancer [2]. According to a study based on the Surveillance, Epidemiology, and End Results database, it is known that about 45% of metastatic gastric cancers are accompanied by liver metastasis (LM) [3]. In addition to peritoneal carcinomatosis, LM is an established poor prognostic factor of gastric cancer [4].","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 2","pages":"251-252"},"PeriodicalIF":3.2000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d2/1b/jgc-23-251.PMC10154135.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gastric Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5230/jgc.2023.23.e21","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The RAINBOW study is a phase 3 trial comparing the combination therapy of ramucirumab plus paclitaxel with paclitaxel monotherapy as palliative second-line treatment in patients with gastric or gastroesophageal junction adenocarcinoma [1]. A significant increase in both the median overall survival (OS, 9.6 vs 7.4 months) and progression-free survival (PFS, 4.4 vs. 2.9 months) was observed in patients who received ramucirumab plus paclitaxel. Based on this pivotal study, ramucirumab plus paclitaxel is the standard second-line treatment. The liver is one of the most common sites of metastasis of gastrointestinal cancer [2]. According to a study based on the Surveillance, Epidemiology, and End Results database, it is known that about 45% of metastatic gastric cancers are accompanied by liver metastasis (LM) [3]. In addition to peritoneal carcinomatosis, LM is an established poor prognostic factor of gastric cancer [4].
期刊介绍：
The Journal of Gastric Cancer (J Gastric Cancer) is an international peer-reviewed journal. Each issue carries high quality clinical and translational researches on gastric neoplasms. Editorial Board of J Gastric Cancer publishes original articles on pathophysiology, molecular oncology, diagnosis, treatment, and prevention of gastric cancer as well as articles on dietary control and improving the quality of life for gastric cancer patients. J Gastric Cancer includes case reports, review articles, how I do it articles, editorials, and letters to the editor.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
